Q-omics provides the consensus-scored ACVR2B-AS1 profile across patient tissues and cancer cell-line models. ACVR2B-AS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ACVR2B-AS1 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, ACVR2B-AS1 RNA expression shows 19,397 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, STAD, and LSCC as cancer lineages where ACVR2B-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACVR2B-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACVR2B-AS1 survival associations across molecular data types. ACVR2B-AS1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACVR2B-AS1 RNA expression–survival associations across cancer types. High ACVR2B-AS1 expression shows unfavorable associations in LIHC, but favorable associations in UVM, KIRC, BRCA, LUAD and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ACVR2B-AS1 RNA expression.
This table summarizes ACVR2B-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACVR2B-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACVR2B-AS1 shows lower tumor expression in STAD, THCA, UCEC, BRCA and KIRC and higher tumor expression in LIHC. The STAD box plot shows higher ACVR2B-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.491, t-test p = .003).
This table shows molecular features associated with ACVR2B-AS1 in patient tissues and cancer cell lines. In patient samples, ACVR2B-AS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACVR2B-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
